Circulating CD3+CD4+CD161+ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma
Table 1
Patient characteristics.
Characteristic
Total () (%)
Age, years, median (range)
56 (32–67)
Sex (M/F)
64 (59)/44 (41)
BMI (kg/m2), median (range)
24.6 (17.6–33.0)
Serum M-protein
IgG, kappa
28 (26)
IgG, lambda
31 (29)
IgA, kappa
5 (5)
IgA, lambda
9 (8)
Light chain, kappa
11 (10)
Light chain, lambda
17 (16)
Other
7 (6)
Durie-Salmon stage
I-II
14 (13)
IIIA/B
73 (68)/21 (19)
Cytogenetics
Standard risk/high risk/NA
38 (35)/46 (43)/24 (22)
Myeloma bone disease on plain radiographs, yes/no
64 (59)/44 (41)
Creatinine at diagnosis, mg/dL, median (range)
1.02 (0.55–11.61)
β2-microglobulin at diagnosis, mg/mL, median (range)
3.46 (0.2–44.0)
Duration from diagnosis to ASCT, months, median (range)
6.8 (2.9–21.6)
At the time of ASCT
Creatinine, mg/dL, median (range)
0.70 (0.34–10.28)
GFR, ml/min/1.73 m2, median (range)
104.62 (5.11–208.22)
Diabetes
13 (12)
Arrhythmia/cardiac/heart valve disease
2 (2)/5 (5)/0 (0)
Pulmonary
Mild/moderate/severe
17 (16)/45 (42)/25 (23)
Hepatic
Mild/moderate-severe
15 (14)/0 (0)
HCT-CI
0–4/≥4
63 (58)/45 (42)
ASCT, autologous stem cell transplantation; BMI, body mass index; GFR, glomerular filtration rate; HCT-CI, hematopoietic cell transplantation comorbidity index; NA, not available. High-risk cytogenetics was defined as hypodiploidy or deletion of chr13 on conventional cytogenetics or presence of t(4;14), t(14;16), and -17p on fluorescent in situ hybridization and/or conventional cytogenetics. All other cytogenetic abnormalities were considered standard risk. Modification of diet in renal disease (MDRD) GFR was used.
